300110 Huaren Pharmaceutical
- 3.55
- +0.21+6.29%
Huaren Pharmaceutical News
Huaren Pharmaceutical (SZSE:300110) Has A Pretty Healthy Balance Sheet
Huaren Pharmaceutical (300110.SZ): The monkeypox virus nucleic acid detection kit has obtained the CE certification of the European Union.
Huaren Pharmaceutical (300110.SZ) stated on the investor interaction platform on August 13th that the company's monkeypox virus nucleic acid detection kit has obtained EU CE certification. At present, no domestic registration certificate has been obtained, and the company will continue to follow relevant matters.
Huaren Pharmaceutical's Unit Gets Nod to Register Pentoxifylline
Huaren Pharmaceutical (300110.SZ): Its subsidiary Anhui Hengxing Pharmaceutical has obtained a drug registration certificate for its Ketamine Hydrochloride Injection.
On August 5, Gelunhui reported that Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui Hengxing Pharmaceutical") has received the "Drug Registration Certificate" for Ketococonazole Injection approved and issued by the National Medical Products Administration. Ketococonazole Injection is suitable for peripheral arterial disease (intermittent claudication or rest pain) and inner ear circulation disorder, and is a category B medical insurance product in China.
Huaren Pharmaceutical (300110.SZ): Its subsidiary has obtained a medical instruments registration certificate for disposable nasal oxygen tubes.
On July 18th, Gelonhui reported that Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., recently received a registration certificate for medical instruments for the disposable nasal oxygen tube approved and issued by the Shandong Provincial Drug Administration.
Is It Smart To Buy Huaren Pharmaceutical Co., Ltd. (SZSE:300110) Before It Goes Ex-Dividend?
Huaren Pharmaceutical (300110.SZ) plans to distribute 0.21 yuan per 10 shares on July 10th ex-dividend.
Huaren Pharmaceutical (300110.SZ) announced that the annual equity distribution plan for the year 2023 is as follows: a cash dividend of RMB 1.00 (tax included) will be distributed to all shareholders for every 10 shares held.
Huaren Pharmaceutical (300110.SZ): terminates the previous change of the actual controller and again plans, where Xi'an State-owned Assets Supervision and Administration Commission may become the actual controller.
Huaren Pharmaceutical (300110.SZ) announced that its indirectly controlled shareholder, Xi'an Qujiang Cultural and Financial Holdings (Group) ...
Huaren Pharmaceutical (300110.SZ): Hemodialysis fluid (lactate-G1.5%) and Hemodialysis fluid (lactate-G2.5%) have undergone consistency evaluation and optimized production processes and quality standards.
On June 20th, Glonhui reported that Huaren Pharmaceutical (Stock Code: 300110.SZ) has recently received the "Drug Supplement Application Approval Letter" issued by the National Medical Products Administration for the peritoneal dialysis solution (lactate-G1.5%) and peritoneal dialysis solution (lactate-G2.5%). After examination, the product has passed the evaluation for the consistency of quality and efficacy of generic drugs. The following changes have been approved as well: 1. Changing the prescription and production process of the drug; 2. Changing the quality standard of the drug; 3. Revising the drug instructions; 4. Changing the packaging materials and containers that come into direct contact with the drug. Production process and quality standard.
Huaren Pharmaceutical (300110.SZ): Subsidiary re-certified as a high-tech enterprise.
On June 17th, Gelunhui announced that its subsidiary, Hubei Huaren Tongji Pharmaceutical Co., Ltd., received the High-Tech Enterprise Certificate jointly issued by the Science and Technology Department, Finance Department and State Taxation Bureau of Hubei Province. Its wholly-owned subsidiary, Guangxi Yuyuan Pharmaceutical Co., Ltd., received the High-Tech Enterprise Certificate jointly issued by the Science and Technology Department, Finance Department and State Taxation Bureau of Guangxi Zhuang Autonomous Region, respectively and passed the re-evaluation of high-tech enterprises.
Huaren Pharmaceutical's Unit Gets Certificate to Register Disposable Gastrointestinal Nutrition Infusion Tube
Huaren Pharmaceutical (300110.SZ) has obtained the registration certificate for medical instruments for "disposable gastrointestinal nutrition infusion tubing".
On June 12th, Gelunhui reported that Huaren Pharmaceutical (300110.SZ) recently announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., received the "Medical Device Registration Certificate" for the "disposable gastrointestinal nutrition infusion tube" issued by the Shandong Provincial Drug Administration.
Huaren Pharmaceutical (300110.SZ) subsidiary salbutamol sulfate injection obtained drug registration certificate
Huaren Pharmaceutical (300110.SZ) issued an announcement. Recently, Anhui Hengxing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (...
Huaren Pharmaceutical (300110.SZ): Low-calcium peritoneal dialysis solution (lactate-G 1.5%, G 2.5%, G 4.25%) obtained approval notice for drug supplementation applications
On May 14, Ge Longhui Pharmaceutical (300110.SZ) announced that it has received the “Drug Supplement Application Approval Notice” for a total of 3 types of products: low calcium peritoneal dialysis solution (lactate-G 1.5%), low calcium peritoneal dialysis solution (lactate-G 2.5%), and low calcium peritoneal dialysis solution (lactate-G 4.25%), approved and issued by the State Drug Administration. Low-calcium peritoneal dialysis solutions (lactate-G 1.5%, G 2.5%, G 4.25%) are suitable for patients with chronic renal failure who require continuous recumbent peritoneal dialysis treatment due to ineffectiveness of non-dialysis treatment. They are all Class A products of the National Medical Insurance
Huaren Pharmaceutical (300110.SZ): The subsidiary obtained a medical device registration certificate for a “disposable peripheral blood collector”
Gelonghui, May 10 丨 Huaren Pharmaceutical (300110.SZ) announced that recently, Qingdao Huaren Medical Products Co., Ltd., a wholly-owned subsidiary of Huaren Pharmaceutical Co., Ltd., received a “Medical Device Registration Certificate” for a “disposable peripheral blood collector” approved and issued by the Shandong Drug Administration
Huaren Pharmaceutical (300110.SZ): Bai Peng and Meng Xiangyuan were appointed as vice presidents
Huaren Pharmaceutical (300110.SZ) issued an announcement. The company will hold the 8th board meeting on April 23, 2024...
Huaren Pharmaceutical (300110.SZ) announced its 2023 annual results, with net profit of 188 million yuan, an increase of 4.03% over the previous year
Huaren Pharmaceutical (300110.SZ) announced its 2023 annual results, with operating revenue of 1,636 billion yuan, a year-on-year increase...
Huaren Pharmaceutical Co., Ltd.'s (SZSE:300110) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Huaren Pharma's Unit Gets Nod for Medical Device
Huaren Pharmaceutical (300110.SZ): Use a disposable infusion joint disinfection cap to obtain a medical device registration certificate
Gelonghui, April 3, 丨 Huaren Pharmaceutical (300110.SZ) announced that recently, Qingdao Huaren Medical Products Co., Ltd., a wholly-owned subsidiary of Huaren Pharmaceutical Co., Ltd., received the “Medical Device Registration Certificate” for the “disposable infusion joint disinfection cap” approved and issued by the Shandong Drug Administration. The company's disposable infusion joint disinfection cap, which has obtained a registration certificate, consists of a case, sponge, 70% isopropyl alcohol, and sealing protective film. It can be used not only for physical barrier needleless joints (outer cone locking joints) of infusion (injection) instruments, but also for disinfecting needleless joints of infusion (injection) devices. Product Registration Categories
Analysis
Price Target
No Data
